The use of interleukin-2 in human immunodeficiency virus infection.
Advances in antiretroviral therapy for human immunodeficiency virus (HIV) have led to reductions in HIV-related morbidity and mortality. Although antiretroviral therapy has shown success in suppressing viral loads, it does not adequately restore the immune system in all individuals infected with HIV. In light of this incomplete success, interleukin (IL)-2 is being evaluated as adjunctive therapy to antiretroviral therapy. The agent has demonstrated mixed yet promising results in restoring immune function in patients who are HIV positive.